Citations

Clear

1446 citation(s) found for "Howard, F".

Abstract P564: Hypertriglyceridemia as a Treatment Target in Asymptomatic Carotid Stenosis
Voeks, Jenifer H. , Teal, Philip , Chimowitz, Marc I. , Barrett, Kevin M. , Lazar, Ronald M. , Moy, Claudia S., Moore, Wesley S. , Roubin, Gary S., Brown, Robert D. , Lal, Brajesh K. , Brott, Thomas G. , Chaturvedi, Seemant , Turan, Tanya N. , Goldstein, Jeffrey A. , Demaerschalk, Bart M. , Howard, Virginia J. , Meschia, James F. , Howard, George

Mayo Clinic

Stroke | March 11, 2021 | Volume: 52 | Issue: Suppl_1 | Pages: No page available

10.1161/str.52.suppl_1.p564 Get It

Background: Data from the CDC show that approximately one-quarter of adults have elevated triglyceride (TG) levels. Recent trials have demonstrated that pharmacologic treatment of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events such as myocardial infarction and stroke (REDUCE-IT trial). We sought to assess how often patients with asymptomatic carotid stenosis (CS) have elevated TG levels and factors associated with high TG values. Methods: Patients enrolled in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST 2) were analyzed. Baseline lipid profiles were evaluated to determine high TG treatment eligibility as per the REDUCE-IT trial. We also evaluated baseline use of pharmacologic treatment for high TG levels. Demographic factors and baseline medical conditions were studied in relation to high (>150 mg/dl) TG values. Chi square and t tests were used to assess baseline factors and abnormal TG values. Results: As of August 10, 2020, 1655 of 1689 randomized patients (mean age 69.7 years, 61% men) had baseline lipid profiles suitable for analysis. Treatment eligibility according to REDUCE-IT (LDL 41-100 mg/dl, TG>150 mg/dl) was present in 21% (345) of subjects. In these patients, the median TG value was 205 (IQR 93) mg/dl. Fibrate medications were used at baseline in 4.5% of patients. Analysis of demographic and medical history factors and TG values greater than 150 mg/dl is found in the Table. There was significant positive correlation between baseline hemoglobin A1C and triglyceride values (p<0.0001) Conclusions: One in five patients in CREST 2 has TG values that potentially justify pharmacologic treatment. Elevated TG levels are most correlated with diabetes, hypertension, obesity, decreased physical activity, and heart disease. Clinicians should investigate treatment of elevated TG levels as a component of intensive medical therapy for stroke prevention.
Abstract MP44: Sex and Outcomes After Carotid Stenting and Endarterectomy for Asymptomatic Patients: A Pooled Analysis of the Crest and Act I Trials
Voeks, Jenifer H. , Roubin, Gary S., Brott, Thomas G. , Matsumura, Jon S. , Hanlon, Bret M. , Panthofer, Annalise M. , Howard, Virginia J. , Howard, George , Rosenfield, Kenneth

Mayo Clinic

Stroke | March 11, 2021 | Volume: 52 | Issue: Suppl_1 | Pages: No page available

10.1161/str.52.suppl_1.mp44 Get It

Introduction: Previous analyses of randomized trials comparing carotid artery stenting (CAS) versus carotid endarterectomy (CEA) have revealed varying sex-associated risk. To better understand sex as an effect modifier in the asymptomatic population, we combined the asymptomatic patients from CREST with the asymptomatic patients from ACT I. Methods: We analyzed data from 2544 subjects with ≥ 70% carotid stenosis randomized to CAS or CEA in addition to standard management of cardiovascular risk factors. CREST enrolled 1091 (548 CAS, 543 CEA) and ACT I enrolled 1453 (1089 CAS, 364 CEA) asymptomatic patients less than 80 years old (upper age eligibility in ACT I). We examined the impact of sex on risk within CAS-treated and CEA-treated patients using Kaplan-Meier methods. The pre-specified, primary composite endpoint was stroke, myocardial infarction, or death during the periprocedural period (within 30 days of randomization) or any ipsilateral stroke within 4 years after randomization. Results: For patients assigned to CAS, there was no difference in risk between the sexes (female-to-male HR = 1.04, 95% CI 0.65 -- 1.66, P = 0.87). For patients assigned to CEA, the difference in risk detected was not significant (female-to-male HR = 1.43, 95% CI 0.77 - 2.67, P = 0.26). Conclusions: Sex-differences in risk were not significant for those assigned CAS nor those assigned CEA in this largest pooled analysis of asymptomatic patients comparing CAS to CEA.
Healthcare disparities among anticoagulation therapies for severe COVID‐19 patients in the multi‐site VIRUS registry
Kirkup, Christian , Puranik, Arjun, Conrad, Ian, Gomaa, Dina , Mosier, Jarrod , Заболотских, И. Б. , Daugherty, Steven K., Bernstein, Michael, Zaren, Howard A. , Bansal, Vikas , Pickering, Brian , Badley, Andrew D. , Camazine, Maraya , Koritala, Thoyaja , O'Horo, John C, Bansal, Vikas , Soundararajan, Venky , Badley, Andrew D , Mosier, Jarrod M , Pawlowski, Colin , O’Horo, John C. , Banner‐Goodspeed, Valerie , Kashyap, Rahul , Venkatakrishnan, A J , Soundararajan, Venky

Mayo Clinic

Journal of Medical Virology | March 5, 2021 | Volume: 93 | Issue: 7 | Pages: 4303-4318

10.1002/jmv.26918 | PMID 33666246 Get It

Abstract Here we analyze hospitalized andintensive care unit coronavirus disease 2019 (COVID‐19) patient outcomes from the international VIRUS registry ( https://clinicaltrials.gov/ct2/show/NCT04323787 ). We find that COVID‐19 patients administered unfractionated heparin but not enoxaparin have a higher mortality‐rate (390 of 1012 = 39%) compared to patients administered enoxaparin but not unfractionated heparin (270 of 1939 = 14%), presenting a risk ratio of 2.79 (95% confidence interval [CI]: [2.42, 3.16]; p = 4.45e−52). This difference persists even after balancing on a number of covariates including demographics, comorbidities, admission diagnoses, and method of oxygenation, with an increased mortality rate on discharge from the hospital of 37% (268 of 733) for unfractionated heparin versus 22% (154 of 711) for enoxaparin, presenting a risk ratio of 1.69 (95% CI: [1.42, 2.00]; p = 1.5e−8). In these balanced cohorts, a number of complications occurred at an elevated rate for patients administered unfractionated heparin compared to patients administered enoxaparin, including acute kidney injury, acute cardiac injury, septic shock, and anemia. Furthermore, a higher percentage of Black/African American COVID patients (414 of 1294 [32%]) were noted to receive unfractionated heparin compared to White/Caucasian COVID patients (671 of 2644 [25%]), risk ratio 1.26 (95% CI: [1.14, 1.40]; p = 7.5e−5). After balancing upon available clinical covariates, this difference in anticoagulant use remained statistically significant (311 of 1047 [30%] for Black/African American vs. 263 of 1047 [25%] for White/Caucasian, p = .02, risk ratio 1.18; 95% CI: [1.03, 1.36]). While retrospective studies cannot suggest any causality, these findings motivate the need for follow‐up prospective research into the observed racial disparity in anticoagulant use and outcomes for severe COVID‐19 patients.
Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.
Khairnar, Rahul , Olives, Ester Villalonga , Shah, Amit B. , Malone, Shawn , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Albert, Michele, Pisansky, Thomas M. , Chen, Yuhchyau , Horwitz, Eric M. , DeNittis, Albert S., DeMora, Lyudmila, Feng, Felix Y. , Villalonga-Olives, Ester , Dayes, Ian S , Seaward, Samantha A , Sandler, Howard M. , Lee, W. Robert , Mullins, C. Daniel , Bruner, Deborah Watkins , Currey, Adam D. , Mishra, Mark V.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 60-60

10.1200/jco.2021.39.6_suppl.60 Get It

60 Background: Mapping algorithms informing economic evaluations are often derived using baseline data from clinical trials. It is unclear if these algorithms can predict health utilities accurately in post-intervention data. Thus, this study examines the longitudinal predictive ability of mapping algorithms derived from baseline trial data and explores the factors associated with prediction errors. Methods: This methodological study utilized data from an international, multicenter, randomized controlled trial of patients with low-risk prostate cancer (PC), conducted by NRG Oncology (NCT00331773). In addition to patient demographic and clinical data, this study utilized PRO data collected at baseline and 6, 12 and 24 months post-intervention. The Expanded Prostate Cancer Index Composite (EPIC) questionnaire measures health-related quality-of-life (HRQoL) and has four domains (urinary, sexual, hormonal, and bowel) and two subdomains per domain (function and bother); EuroQOL-5D-3L (EQ5D) captures health utilities. Ordinary Least Squares (OLS) regression models were used to map EPIC scores to EQ5D utilities in the baseline data through 5-fold cross-validation. Predictive performance was tested in the post-intervention data; predicted and reported utilities were compared using t-tests, and the absolute prediction error was modeled using fixed effects, as a function of baseline demographic and clinical covariates, as well as observed and predicted EQ5D utilities. Results: A total of 267 (199) patients had complete EQ5D and EPIC domain (or subdomain) data at baseline and all subsequent assessments. In the EPIC domain sample, mean ± standard deviation observed EQ5D utility was 0.90±0.13 at baseline, 0.92±0.11 at 6 months, 0.90±0.13 at 12 months and 0.89±0.14 at 24 months. Mean absolute differences (MDs) between reported and predicted were lower for models using EPIC subdomain data compared to EPIC domain data, and generally decreased as the time of assessment increased. The mapping functions over-predicted utilities for patients in perfect health while the prediction errors were increasingly negative for lower reported EQ5D scores. According to the fixed effects model for EPIC domain data, lower observed and predicted baseline EQ5D scores, and time of assessment were significant predictors of the absolute prediction error; for EPIC subdomain data, lower observed and predicted baseline EQ5D scores, hormonal bother and function, and bowel function significantly predicted the absolute prediction error. Conclusions: This study is the first to demonstrate the longitudinal validity of EPIC questionnaire, and builds upon existing research on longitudinal validity of mapping functions. The low MDs in prediction errors in post-intervention data indicate that the mapping functions are sensitive to treatment effect, thereby increasing confidence in their use in economic evaluations in PC.
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer
Merritt, Melissa A. , Strickler, Howard D. , Hutson, Alan D. , Rohan, Thomas E. , Xue, Xiaonan , Brinton, Louise A. , Yu, Kai , Miller, David S. , Ramirez, Nilsa C. , Lankes, Heather A. , Birrer, Michael J. , Huang, Gloria S. , Gunter, Marc J. , Brinton, Louise A , Yu, Herbert , Miller, David S , Huang, Gloria S , Gunter, Marc J , Hutson, Alan D , Einstein, Mark H. , Sherman, Mark E.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 23, 2021 | Volume: 30 | Issue: 4 | Pages: 719-726

10.1158/1055-9965.epi-20-1613 | PMID 33622671 Get It

Abstract Background: The influence of sex hormone and insulin/insulin-like growth factor (IGF) axis signaling on endometrial cancer recurrence is unknown. We evaluated these pathways in a prospective cohort of Gynecologic Oncology Group (GOG)0210 trial endometrial adenocarcinoma patients. Methods: Stage II–IV patients (N = 816) were included in this study. Pretreatment specimens were tested for tumor mRNA and protein expression of IGF1, IGF2, IGF-binding proteins (IGFBP)-1 and -3, insulin (IR) and IGF-I receptors (IGF1R), phosphorylated IR/IGF1R (pIGF1R/pIR), and estrogen (ER) and progesterone receptors (PR) using qPCR and IHC. Serum concentrations of insulin, IGF-I, IGFBP-3, estradiol, estrone, and sex hormone binding globulin were measured. HRs and 95% confidence intervals (CI) for progression-free survival were calculated from Cox models adjusting for age, stage, and grade. Results: Recurrence occurred in 280 (34%) cases during a median of 4.6 years of follow-up. ER positivity (HR, 0.67; 95% CI, 0.47–0.95), IR positivity (HR, 0.53; 95% CI, 0.29–0.98), and circulating IGF-I (highest vs. lowest quartile: HR, 0.66; 95% CI, 0.47–0.92) were inversely associated with recurrence risk. Circulating estradiol (highest vs. lowest tertile: HR, 1.55; 95% CI, 1.02–2.36) and pIGF1R/pIR positivity (HR, 1.40; 95% CI, 1.02–1.92) were associated with increased recurrence risk. Conclusions: Circulating estradiol and tumor tissue phosphorylated (activated) IGR1R/IR were independently associated with higher risk of recurrence in patients with endometrial cancer. Impact: This study may inform future clinical trials of endocrine-targeted adjuvant therapies in patients with endometrial cancer that could include baseline assessment of serum and tissue biomarkers of estradiol and insulin signaling pathways.
Uniform data set language measures for bvFTD and PPA diagnosis and monitoring
Staffaroni, Adam M. , Weıntraub, Sandra , Rascovsky, Katya, Rankin, Katherine P. , Taylor, Jack C. , Fields, Julie A. , Casaletto, Kaitlin B. , Gorno‐Tempini, Maria Luisa , Heuer, Hilary W. , Teylan, Merilee, Kukull, Walter A. , Miller, Bruce L. , Rosen, Howard J. , Boxer, Adam L. , Kramer, Joel H. , Miller, Bruce L , Hillis, Argye Elizabeth , Lukic, Sladjana , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | February 20, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12148 | PMID 33665340 Get It

Abstract Introduction The Frontotemporal Lobar Degeneration Module (FTLD‐MOD) includes a neuropsychological battery designed to assess the clinical features of FTLD, although much is unknown about its utility. We investigated FTLD‐MOD and Uniform Data Set 3.0 (UDS) language tests for differential diagnosis and disease monitoring. Methods Linear regressions compared baseline performances in 1655 National Alzheimer's Coordinating Center participants (behavioral variant frontotemporal dementia (bvFTD, n = 612), semantic variant primary progressive aphasia (svPPA, n = 185), non‐fluent/agrammatic variant PPA (nfvPPA, n = 168), logopenic variant PPA (lvPPA, n = 109), and controls (n = 581)). Sample sizes to detect treatment effects were estimated using longitudinal data. Results Among PPAs, the FTLD‐MOD language tasks and UDS Multilingual Naming Test accurately discriminated svPPA. Number Span Forward best discriminated lvPPA; Phonemic:Semantic Fluency ratio was excellent for nfvPPA classification. UDS fluency and naming measures required the smallest sample size to detect meaningful change. Discussion The FTLD‐MOD and UDS differentiated among PPA subtypes. UDS 3.0 measures performed best for longitudinal monitoring.
Seizures and memory impairment induced by patient‐derived anti‐N‐methyl‐D‐aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin‐1 receptor antagonist
Taraschenko, Olga , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Eldridge, Ember, Farukhuddin, FNU , Al‐Saleem, Fetweh H., Kattala, Chandana Devi , Casale, George P. , Willcockson, Gregory, Pittock, S J , Fox, Howard S. , Dessain, Scott K. , Dingledine, Raymond

Mayo Clinic

Epilepsia | February 20, 2021 | Volume: 62 | Issue: 3 | Pages: 671-682

10.1111/epi.16838 | PMID 33596332 Get It

AbstractObjectiveNeuroinflammation associated with anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis may facilitate seizures. We previously showed that intraventricular administration of cerebrospinal fluid from patients with anti‐NMDAR encephalitis to mice precipitates seizures, thereby confirming that antibodies are directly pathogenic. To determine whether interleukin (IL)‐1‐mediated inflammation exacerbates autoimmune seizures, we asked whether blocking the effects of IL‐1 by anakinra, a selective IL‐1 receptor antagonist, blunts antibody‐induced seizures.MethodsWe infused C57BL/6 mice intraventricularly with purified serum IgG from patients with anti‐NMDAR encephalitis or monoclonal anti‐NMDAR IgG; subdural electroencephalogram was continuously recorded. After a 6‐day interval, mice received anakinra (25 mg/kg sc, twice daily) or vehicle for 5 days. Following a 4‐day washout period, we performed behavioral tests to assess motor function, anxiety, and memory, followed by hippocampus tissue analysis to assess astrocytic (glial fibrillary acidic protein [GFAP]) and microglial (ionized calcium‐binding adapter molecule [Iba]‐1) activation.ResultsOf 31 mice infused with purified patient NMDAR‐IgG (n = 17) or monoclonal NMDAR‐IgG (n = 14), 81% developed seizures. Median baseline daily seizure count during exposure to antibodies was 3.9; most seizures were electrographic. Median duration of seizures during the baseline was 82.5 s. Anakinra administration attenuated daily seizure frequency by 60% (p = .02). Anakinra reduced seizure duration; however, the effect was delayed and became apparent only after the cessation of treatment (p = .04). Anakinra improved novel object recognition in mice with antibody‐induced seizures (p = .03) but did not alter other behaviors. Anakinra reduced the expression of GFAP and Iba‐1 in the hippocampus of mice with seizures, indicating decreased astrocytic and microglial activation.SignificanceOur evidence supports a role for IL‐1 in the pathogenesis of seizures in anti‐NMDAR encephalitis. These data are consistent with therapeutic effects of anakinra in other severe autoimmune and inflammatory seizure syndromes. Targeting inflammation via blocking IL‐1 receptor‐mediated signaling may be promising for developing novel treatments for refractory autoimmune seizures.
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining
Zhou, Qin , Howard, Michelle E. , Tu, Xinyi , Zhu, Qian , Denbeigh, Janet M. , Remmes, Nicholas B. , Herman, Michael , Beltran, Chris , Greipp, Patricia T. , Wang, Liewei , Johnson, Neil , Mutter, Robert W. , Herman, Michael G., Beltran, Chris J., Boughey, JC , Beltran, Chris J , Greipp, Patricia T , Yuan, Jian , Boughey, Judy C. , Goetz, Matthew P. , Sarkaria, Jann N. , Lou, Zhenkun

Mayo Clinic

Cancer Research | February 17, 2021 | Volume: 81 | Issue: 12 | Pages: 3333-3346

10.1158/0008-5472.can-20-2960 | PMID 33597272 Get It

Abstract Proton Bragg peak irradiation has a higher ionizing density than conventional photon irradiation or the entrance of the proton beam profile. Whether targeting the DNA damage response (DDR) could enhance vulnerability to the distinct pattern of damage induced by proton Bragg peak irradiation is currently unknown. Here, we performed genetic or pharmacologic manipulation of key DDR elements and evaluated DNA damage signaling, DNA repair, and tumor control in cell lines and xenografts treated with the same physical dose across a radiotherapy linear energy transfer spectrum. Radiotherapy consisted of 6 MV photons and the entrance beam or Bragg peak of a 76.8 MeV spot scanning proton beam. More complex DNA double-strand breaks (DSB) induced by Bragg peak proton irradiation preferentially underwent resection and engaged homologous recombination (HR) machinery. Unexpectedly, the ataxia-telangiectasia mutated (ATM) inhibitor, AZD0156, but not an inhibitor of ATM and Rad3-related, rendered cells hypersensitive to more densely ionizing proton Bragg peak irradiation. ATM inhibition blocked resection and shunted more DSBs to processing by toxic ligation through nonhomologous end-joining, whereas loss of DNA ligation via XRCC4 or Lig4 knockdown rescued resection and abolished the enhanced Bragg peak cell killing. Proton Bragg peak monotherapy selectively sensitized cell lines and tumor xenografts with inherent HR defects, and the repair defect induced by ATM inhibitor coadministration showed enhanced efficacy in HR-proficient models. In summary, inherent defects in HR or administration of an ATM inhibitor in HR-proficient tumors selectively enhances the relative biological effectiveness of proton Bragg peak irradiation. Significance: Coadministration of an ATM inhibitor rewires DNA repair machinery to render cancer cells uniquely hypersensitive to DNA damage induced by the proton Bragg peak, which is characterized by higher density ionization. See related commentary by Nickoloff, p. 3156
Aspiration Thrombectomy: 2-Dimensional Operative Video
Turner, Raymond D , Turk, Aquilla S , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Lanzino, Giuseppe, Levitt, Michael , Levy, Elad, Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Schirmer, Clemens M , Chaudry, Imran , Vargas, Jan , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael, Levy, E, Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | February 12, 2021 | Volume: 20 | Issue: 4 | Pages: E286-E287

10.1093/ons/opaa471 | PMID 33575807 Get It

Abstract Acute ischemic stroke is one of the leading causes of disability and mortality worldwide. There have been significant improvements to the treatment of acute ischemic stroke over the past 5 yr, specifically related to strokes caused by large vessel occlusions. Stent retrievers with and without local aspiration and direct aspiration alone have all been demonstrated as viable treatment options for this patient population. This case represents the surgical technique for direct aspiration for the treatment of large vessel occlusion. A 76-yr-old man presented with right-sided weakness and aphasia. His last known normal was 5 h ago. His NIHSS (National Institutes of Health Stroke Scale) was 18. The noncontrast computed tomography (CT) did not show a significant infarct burden and ASPECTS (Alberta Stroke Program Early CT Score) of 9. CT angiogram demonstrated a left M1 occlusion. The patient was not a candidate for tissue plasminogen activator (tPA) because of time to presentation; however, the patient was deemed to be a candidate for emergent thrombectomy. Consent was obtained per institutional guidelines for the emergent procedure and the video recording. The video demonstrates a direct aspiration thrombectomy technique for the treatment of stroke. The patient successfully underwent direct aspiration thrombectomy with a TICI 3 (thrombolysis in cerebral infarction) recanalization.